Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by Enterobacteriaceae
Sign Up to like & getrecommendations! Published in 2021 at "Antibiotics"
DOI: 10.3390/antibiotics10040469
Abstract: In 2018, the Clinical and Laboratory Standards Institute (CLSI) revised ciprofloxacin (CIP)-susceptible breakpoint for Enterobacteriaceae from ≤1 μg/mL to ≤0.25 μg/mL, based on pharmacokinetic-pharmacodynamic (PK-PD) analysis. However, clinical data supporting the lowered CIP breakpoint are… read more here.
Keywords: urinary tract; breakpoint; cip susceptible; revised ciprofloxacin ... See more keywords